Back to Journals » International Journal of Nanomedicine » Volume 10 » Issue 1

Reducible chimeric polypeptide consisting of octa-d-arginine and tetra-l-histidine peptides as an efficient gene delivery vector
Authors Wang X, Tai Z, Tian J, Zhang W, Yao C, Zhang L, Gao Y, Zhu Q, Gao J, Gao S
Received 25 February 2015
Accepted for publication 12 May 2015
Published 22 July 2015 Volume 2015:10(1) Pages 4669—4690
DOI https://doi.org/10.2147/IJN.S83507
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Lei Yang
Xiaoyu Wang,1,2* Zongguang Tai,1* Jing Tian,1* Wei Zhang,3 Chong Yao,1 Lijuan Zhang,1 Yuan Gao,1 Quangang Zhu,1 Jing Gao,4 Shen Gao1
1Department of Pharmaceutics, Changhai Hospital, Second Military Medical University, Shanghai, 2Department of Pharmaceutics, ChengDu Military General Hospital, ChengDu, 3Department of Pharmaceutics, Shanghai Pulmonary Hospital, Tongji University, Shanghai, 4Department of Pharmaceutical Science, School of Pharmacy, Second Military Medical University, Shanghai, People’s Republic of China
*These authors contributed equally to this work
Abstract: Cationic oligopeptide as a nonviral gene delivery vector has aroused much research interest recently, but its further application is limited by its low transfection efficiency. In the present study, we have created a high-efficiency gene vector by using octa-d-arginine and tetra-l-histidine to form a disulfide cross-linked chimeric polypeptide and used this vector to deliver the therapeutic gene tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) to see whether the gene could be transferred and could exert antitumor effects in vitro and in vivo. The result showed that the newly designed vector was able to condense DNA into nanosized polyplexes effectively, thus facilitating its transmembrane transport, promoting its endosomal escape, and finally enabling degradation within the cell. Our study has demonstrated that this chimeric polypeptide is an effective gene carrier in cancer therapy.
Keywords: reducible polypeptide, disulfide bond, octa-d-arginine, tetra-l-histidine, TRAIL
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.